News
CINGW
0.0350
+21.11%
0.0061
Cingulate Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING)
TipRanks · 4d ago
Weekly Report: what happened at CING last week (0518-0522)?
Weekly Report · 5d ago
Cingulate Reshapes Board Structure and Leadership Roles
TipRanks · 05/19 22:16
Cingulate says directors Ervin, Roberts won’t seek re-election at 2026 annual meeting
PUBT · 05/19 20:51
Cingulate price target lowered to $10 from $14 at Roth Capital
TipRanks · 05/19 15:00
Weekly Report: what happened at CING last week (0511-0515)?
Weekly Report · 05/18 10:36
Cingulate reports Q1 results
Seeking Alpha · 05/14 18:24
Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate
Benzinga · 05/14 12:44
Cingulate FY26 Q1 net loss widens 141.7% to $9.31 million
PUBT · 05/14 12:16
Cingulate Q1 net loss widens more than expected on commercial preparations
Reuters · 05/14 12:12
Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Dow Jones · 05/14 12:00
Weekly Report: what happened at CING last week (0504-0508)?
Weekly Report · 05/11 10:33
Weekly Report: what happened at CING last week (0427-0501)?
Weekly Report · 05/04 10:30
Biotech Stocks Facing FDA Decision In May 2026
NASDAQ · 04/28 12:01
Weekly Report: what happened at CING last week (0420-0424)?
Weekly Report · 04/27 10:33
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/22 21:05
Six new option listings on April 22nd
TipRanks · 04/22 13:47
Weekly Report: what happened at CING last week (0413-0417)?
Weekly Report · 04/20 10:28
Cingulate files to sell 4.21M shares of common stock for holders
TipRanks · 04/14 21:30
More
Webull provides a variety of real-time CINGW stock news. You can receive the latest news about Cingulate through multiple platforms. This information may help you make smarter investment decisions.
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.